Hepatocyte-like cell therapy for end-stage liver disease:From basic science to clinical applicationOA
Hepatocyte-like cell therapy for end-stage liver disease:From basic science to clinical application
Wenwen Ge;Zhoucheng Wang;Yutong Chen;Xiao Tang;Zijian Lou;Jun Chen;Xiao Xu;Kai Wang
Institute of Translational Medicine,Zhejiang University School of Medicine,Hangzhou,Zhejiang,ChinaInstitute of Translational Medicine,Zhejiang University School of Medicine,Hangzhou,Zhejiang,ChinaThe Fourth School of Clinical Medicine,Zhejiang Chinese Medical University,Hangzhou,Zhejiang,ChinaInstitute of Translational Medicine,Zhejiang University School of Medicine,Hangzhou,Zhejiang,ChinaInstitute of Translational Medicine,Zhejiang University School of Medicine,Hangzhou,Zhejiang,ChinaHepatobiliary Center,The First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu,ChinaInstitute of Translational Medicine,Zhejiang University School of Medicine,Hangzhou,Zhejiang,China||Hepatobiliary Center,The First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu,ChinaDepartment of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery,Zhejiang Provincial People's Hospital(Affiliated People's Hospital),School of Clinical Medicine,Hangzhou Medical College,Hangzhou,Zhejiang,China
End-stage liver disease(ESLD)Stem cell differentiationCell reprogrammingCell therapy
End-stage liver disease(ESLD)Stem cell differentiationCell reprogrammingCell therapy
《肝脏研究（英文）》 2026 (1)
10-21,12
This work was supported by the National Key Research and Development Program of China(No.2021YFA1100500),General Program of National Natural Science Foundation of China(No.82470683),and Key Research and Development Program of Zhe-jiang Province(No.2022C03108).
评论